PRODUCT INFORMATION



Ryuvidine

Item No. 16614

CAS Registry No.:	265312-55-8	
Formal Name:	2-methyl-5-[(4-methylphenyl)amino]-	
	4,7-benzothiazoledione o	
Synonyms:	Cdk4 Inhibitor III, Cyclic-dependent	
	Kinase 4 Inhibitor III, SPS812	
MF:	$C_{15}H_{12}N_2O_2S$	
FW:	284.3 N N	
Purity:	≥95%	
UV/Vis.:	λ _{max} : 253, 531 nm	
Supplied as:	A crystalline solid	
Storage:	-20°C	
Stability:	≥4 years	
Information represent	the preduct excellentians. Datch excelled analytical results are provided an each certificate of analysis	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Ryuvidine is supplied as a crystalline solid. A stock solution may be made by dissolving the ryuvidine in the solvent of choice. Ryuvidine is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of ryuvidine in these solvents is approximately 0.5, 2, and 5 mg/ml, respectively.

Ryuvidine is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ryuvidine should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Ryuvidine has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

SET domain-containing protein 8 (SETD8) is a methyltransferase that selectively monomethylates histone H4 at lysine residue 20 (H4K20), an event proven to have an important role in chromatin structure and transcriptional activation. It is also a regulator of p53, mono-methylating lysine 382 of the tumor suppressor. Ryuvidine is an inhibitor of SETD8 (IC₅₀ = 0.5 μ M) that suppresses monomethylation of H4K20 in vitro.¹ It less potently inhibits cyclin-dependent kinase 4 (Cdk4; IC₅₀ = 6 μ M for Cdk4/cyclin D1).² Over several hours of treatment, ryuvidine suppresses the expression of cell division cycle 7-related kinase (Cdc7), resulting in an ATM-dependent checkpoint response and arrest of cell cycling in S phase.^{1,3}

References

- 1. Blum, G., Ibáñez, G., Rao, X., et al. Small-molecule inhibitors of SETD8 with cellular activity. ACS Chem. Biol. 9(11), 2471-2478 (2014).
- 2. Ryu, C.K., Kang, H.Y., Lee, S.K., et al. 5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. Bioorg. Med. Chem. Lett. 10(5), 461-464 (2000).
- 3. FitzGerald, J., Murillo, L.S., O'Brien, G., et al. A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response. PLoS One 9(6), (2014).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/16/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM